Sanofi/Regeneron Dupixent shows efficacy in kids with esophagus inflammation in phase 3 trial

Oct. 11, 2022 5:34 AM ETSanofi (SNY), REGNBy: Ravikash, SA News Editor

Sanofi Distribution Centre in Kirkland, Quebec, Canada.


Sanofi (NASDAQ:SNY) and Regeneron Pharmaceuticals (NASDAQ:REGN) said their medicine Dupixent showed positive results in a phase 3 trial to treat children aged one to 11 years with active eosinophilic esophagitis (EoE).

EoE is a chronic and progressive inflammatory

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.